Atazanavir Uses

sponsored
How do you administer this medicine?

What is Atazanavir?

Atazanavir is used together with other medicines for the treatment of the infection caused by the human immunodeficiency virus (HIV). HIV is the virus that causes acquired immune deficiency syndrome (AIDS).

Atazanavir will not cure or prevent HIV infection or AIDS. It helps keep HIV from reproducing and appears to slow down the destruction of the immune system. This may help delay problems that are usually related to AIDS or HIV disease from occurring. Atazanavir will not keep you from spreading HIV to other people. People who receive Atazanavir may continue to have other problems usually related to AIDS or HIV disease.

Atazanavir is available only with your doctor's prescription.

Atazanavir indications

infoAn indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored

In combination with other antiretroviral agents for the treatment of HIV-1 infection. This indication is based on analyses of plasma HIV-1 RNA levels and CD4+ cell counts from controlled studies of 96 weeks duration in antiretroviral-naive and 48 weeks duration in antiretroviral treatment-experienced patients.

The following points should be considered when initiating therapy with Atazanavir: In study AI424-045 Atazanavir/ritonavir and lopinavir/ritonavir were similar for the primary efficacy outcome measure of time-averaged difference in change from baseline in HIV RNA level. This study was not large enough to reach a definitive conclusion that Atazanavir/ritonavir and lopinavir/ritonavir are equivalent on the secondary efficacy outcome measure of proportions below the HIV RNA lower limit of detection.

The number of baseline primary PI mutations affects the virologic response to Atazanavir/ritonavir.

How should I use Atazanavir?

Give Atazanavir powder for oral suspension as directed by the doctor. Check the label on the medicine for exact dosing instructions.

  • An extra patient leaflet is available with Atazanavir powder for oral suspension. Talk to your pharmacist if you have questions about this information.
  • Give Atazanavir powder for oral suspension by mouth with food.
  • Before giving, mix the powder with soft food (eg, applesauce, yogurt). If you cannot do this, mix with a drink (eg, milk, infant formula, water). Mix Atazanavir powder for oral suspension as the doctor has told you or read the package insert.
  • If you use infant formula to mix the powder, give the medicine using an oral dosing syringe. Do not give using an infant bottle.
  • Give Atazanavir powder for oral suspension within 1 hour of mixing.
  • If your child also takes an Hantagonist (eg, cimetidine) or a proton pump inhibitor (PPI) (eg, omeprazole), talk with the doctor about how to give it with Atazanavir powder for oral suspension.
  • If your child also takes an antacid or didanosine, give Atazanavir powder for oral suspension at least 2 hours before or 1 hour after the antacid or didanosine.
  • Give Atazanavir powder for oral suspension on a regular schedule to be sure your child gets the most benefit from it.
  • Giving Atazanavir powder for oral suspension at the same time each day will help you remember to give it.
  • Continue to give Atazanavir powder for oral suspension even if your child feels well. Do not miss giving your child any doses.
  • If you miss giving your child a dose of Atazanavir powder for oral suspension, give it as soon as possible. If it is almost time for your child's next dose, skip the missed dose and go back to your child's regular dosing schedule. Do not give 2 doses at once.

Ask the health care provider any questions you may have about how to give Atazanavir powder for oral suspension.

Uses of Atazanavir in details

infoThere are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
sponsored

Atazanavir is used in combination with other anti-retroviral medicines for the treatment of human immunodeficiency virus (HIV-1) infection.

Atazanavir description

Each capsule also contains the following inactive ingredients: Crospovidone, lactose monohydrate and magnesium stearate. Capsule Shell: Gelatin, FD&C Blue No. 2, titanium dioxide, black iron oxide, red iron oxide and yellow iron oxide. The capsules are printed with ink containing shellac, titanium dioxide, FD&C Blue No. 2, isopropyl alcohol, ammonium hydroxide, propylene glycol, n-butyl alcohol, simethicone and dehydrated alcohol.

Atazanavir sulfate is a white to pale yellow crystalline powder. It is slightly soluble in water (4-5 mg/mL, free base equivalent) with the pH of a saturated solution in water being about 1.9 at 24±3°C.

Atazanavir sulfate is (3S,8S,9S,12S)-3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pentaazatetradecanedioic acid dimethyl ester, sulfate (1:1). Its molecular formula is C38H52N6O7·H2SO4, which corresponds to a molecular weight of 802.9 (sulfuric acid salt). The free base molecular weight is 704.9.

Atazanavir dosage

sponsored

Overview

  • Atazanavir capsules and oral powder must be taken with food.
  • Do not open the capsules.
  • The recommended oral dosage of Atazanavir depends on the treatment history of the patient and the use of other coadministered drugs. When coadministered with H2-receptor antagonists or proton-pump inhibitors, dose separation may be required.
  • Atazanavir capsules without ritonavir are not recommended for treatment-experienced adult or pediatric patients with prior virologic failure.
  • Atazanavir oral powder must be taken with ritonavir and is not recommended for use in children who weigh less than 10 kg or who weigh 25 kg or more.
  • Efficacy and safety of Atazanavir with ritonavir when ritonavir is administered in doses greater than 100 mg once daily have not been established. The use of higher ritonavir doses may alter the safety profile of Atazanavir (cardiac effects, hyperbilirubinemia) and, therefore, is not recommended. Prescribers should consult the complete prescribing information for ritonavir when using ritonavir.

Dosage In Adult Patients

Table 1 displays the recommended dosage of Atazanavir capsules in treatment-naive and treatment-experienced adults. Table 1 also displays recommended dosage of Atazanavir and ritonavir when given concomitantly with other antiretroviral drugs and H2-receptor antagonists (H2RA). Ritonavir is required with several Atazanavir dosage regimens. The use of Atazanavir in treatment-experienced adult patients without ritonavir is not recommended.

Table 1: Recommended Atazanavir and Ritonavir Dosage in Adultsa

Atazanavir Once Daily Dosage Ritonavir Once Daily Dosage
Treatment-Naive Adult Patients
recommendedregimen 300 mg 100 mg
unable to tolerate ritonavir 400 mg N/A
in combination with efavirenz 400 mg 100 mg
Treatment-Experienced Adult Patients
recommendedregimen 300 mg 100 mg
in combination with both H2RA and tenofovir 400 mg 100 mg
Atazanavir is not recommended for treatment-experienced pregnant patients during the second and third trimester taking Atazanavir with both tenofovir and H2RA.

Renal Impairment

For patients with renal impairment, including those with severe renal impairment who are not managed with hemodialysis, no dose adjustment is required for Atazanavir. Treatment-naive patients with end stage renal disease managed with hemodialysis should receive Atazanavir 300 mg with ritonavir 100 mg. Atazanavir should not be administered to HIV-treatmentexperienced patients with end stage renal disease managed with hemodialysis.

Dosage Adjustments In Patients With Hepatic Impairment

Table 5 displays the recommended Atazanavir dosage in treatment-naive patients with hepatic impairment. The use of Atazanavir in patients with severe hepatic impairment (Child-Pugh Class C) is not recommended. The coadministration of Atazanavir with ritonavir in patients with any degree of hepatic impairment is not recommended.

Table 5: Recommended Dosage of Atazanavir Capsules in Treatment-Naive Adults with Hepatic Impairment

Atazanavir Once Daily Dosage
Mild hepatic impairment (Child-Pugh Class A) 400 mg
Moderate hepatic impairment (Child-Pugh Class B) 300 mg
Severe hepatic impairment (Child-Pugh Class C) Atazanavir with or without ritonavir is not recommended

How supplied

Dosage Forms And Strengths

Atazanavir Capsules
  • 150 mg capsule with blue cap and powder blue body, printed with white ink “BMS 150 mg” on the cap and with blue ink “3624” on the body.
  • 200 mg capsule with blue cap and blue body, printed with white ink “BMS 200 mg” on the cap and with white ink “3631” on the body.
  • 300 mg capsule with red cap and blue body, printed with white ink “BMS 300 mg” on the cap and with white ink “3622” on the body.
Atazanavir

Oral Powder

  • 50 mg of Atazanavir as an oral powder in a packet.

Storage And Handling

Atazanavir Capsules

Atazanavir® (Atazanavir) capsules are available in the following strengths and configurations of plastic bottles with child-resistant closures.

Product Strength* Capsule Shell Color (cap/body) Markings on Capsule (ink color) Capsules per Bottle NDC Number
cap body
150 mg blue/powder blue BMS 150 mg (white) 3624 (blue) 60 0003-3624-12
200 mg blue/blue BMS 200 mg (white) 3631 (white) 60 0003-3631-12
300 mg red/blue BMS 300 mg (white) 3622 (white) 30 0003-3622-12
* 150 mg Atazanavir equivalent to 170.8 mg Atazanavir sulfate. 200 mg Atazanavir equivalent to 227.8 mg Atazanavir sulfate. 300 mg Atazanavir equivalent to 341.69 mg Atazanavir sulfate.

Store Atazanavir capsules at 25°C (77°F); excursions permitted to 15°C-30°C (59°F-86°F).

Atazanavir

Oral Powder

Atazanavir oral powder is an orange-vanilla flavored powder, packed in child-resistant packets. Each packet contains 50 mg of Atazanavir equivalent to 56.9 mg of Atazanavir sulfate in 1.5 g of powder. Atazanavir oral powder is supplied in cartons (NDC 0003-3638-10) of 30 packets each.

Store Atazanavir oral powder below 30°C (86°F). Once the Atazanavir oral powder is mixed with food or beverage, it may be kept at room temperature 20°C to 30°C (68°F-86°F) for up to 1 hour prior to administration. Store Atazanavir oral powder in the original packet and do not open until ready to use.

Distributed by: Bristol-Myers Squibb Company Princeton, NJ 08543 USA. Issued: June 2014

Atazanavir interactions

See also:
What other drugs will affect Atazanavir?

sponsored

See also Contraindications and Pharmacokinetics under Actions.

Potential for Atazanavir to Affect Other Drugs: Atazanavir is an inhibitor of CYP3A and UGT1A1. Co-administration of Atazanavir and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects.

Atazanavir is a weak inhibitor of CYP2C8. Caution should be used when Atazanavir without ritonavir is co-administered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel and repaglinide). When Atazanavir with ritonavir is co-administered with substrates of CYP2C8, clinically significant interactions are not expected.

The magnitude of CYP3A-mediated drug interactions on co-administered drug may change when Atazanavir is co-administered with ritonavir.

Potential for Other Drugs to Affect Atazanavir: Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease Atazanavir plasma concentrations and reduce Atazanavir’s therapeutic effect.

Atazanavir solubility decreases as pH increases. Reduced plasma concentrations of Atazanavir are expected if PPIs, antacids, buffered medications or H2-receptor antagonists are administered with Atazanavir.

Established and Other Potentially Significant Drug Interactions: Table 21 provides dosing recommendations as a result of drug interactions with Atazanavir. These recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious events or loss of efficacy.

Drugs with No Observed or Predicted Interactions with Atazanavir: Clinically significant interactions are not expected between Atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2 or CYP2E1. Clinically significant interactions are not expected between Atazanavir when administered with ritonavir and substrates of CYP2C8.

Based on known metabolic profiles, clinically significant drug interactions are not expected between Atazanavir (Atazanavir) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin or erythromycin. Atazanavir does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol). Additionally, no clinically significant drug interactions were observed when Atazanavir was co-administered with methadone, fluconazole, acetaminophen or atenolol.

Atazanavir side effects

See also:
What are the possible side effects of Atazanavir?

The following adverse reactions are discussed in greater detail in other sections of the labeling:

  • cardiac conduction abnormalities
  • rash
  • hyperbilirubinemia
  • nephrolithiasis and cholelithiasis

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Clinical Trial Experience In Adults

Treatment-Emergent Adverse Reactions in Treatment-Naive Patients

The safety profile of Atazanavir in treatment-naive adults is based on 1625 HIV-1 infected patients in clinical trials. 536 patients received Atazanavir 300 mg with ritonavir 100 mg and 1089 patients received Atazanavir 400 mg or higher (without ritonavir).

The most common adverse reactions were nausea, jaundice/scleral icterus, and rash.

Selected clinical adverse reactions of moderate or severe intensity reported in ≥ 2% of treatment-naive patients receiving combination therapy including Atazanavir 300 mg with ritonavir 100 mg and Atazanavir 400 mg (without ritonavir) are presented in Tables 7 and 8, respectively.

Table 7: Selected Treatment-Emergent Adverse ReactionsFasting.

Clinical Trial Experience In Pediatric Patients

Adverse Reactions in Pediatric Patients: Atazanavir Capsules

The safety and tolerability of Atazanavir Capsules with and without ritonavir have been established in pediatric patients at least 6 years of age from the open-label, multicenter clinical trial PACTG 1020A.

The safety profile of Atazanavir in pediatric patients (6 to less than 18 years of age) taking the capsule formulation was generally similar to that observed in clinical studies of Atazanavir in adults. The most common Grade 2–4 adverse events ( ≥ 5%, regardless of causality) reported in pediatric patients were cough (21%), fever (18%), jaundice/scleral icterus (15%), rash (14%), vomiting (12%), diarrhea (9%), headache (8%), peripheral edema (7%), extremity pain (6%), nasal congestion (6%), oropharyngeal pain (6%), wheezing (6%), and rhinorrhea (6%). Asymptomatic second-degree atrioventricular block was reported in < 2% of patients. The most common Grade 3–4 laboratory abnormalities occurring in pediatric patients taking the capsule formulation were elevation of total bilirubin ( ≥ 3.2 mg/dL, 58%), neutropenia (9%), and hypoglycemia (4%). All other Grade 3–4 laboratory abnormalities occurred with a frequency of less than 3%.

Adverse Reactions in Pediatric Patients: Atazanavir

Oral Powder

The data described below reflect exposure to Atazanavir oral powder in 89 subjects weighing from 10 kg to less than 25 kg, including 65 patients exposed for 48 weeks. These data are from two pooled open-label, multi-center clinical trials in treatment-naive and treatment-experienced pediatric patients (AI424-397 [PRINCE I] and AI424-451 [PRINCE II]). Age ranged from 15 months to less than 7.5 years of age. In these studies 53% were female and 47% were male. All patients received ritonavir and 2 nucleoside reverse transcriptase inhibitors (NRTIs).

The safety profile of Atazanavir in pediatric patients taking Atazanavir oral powder was generally similar to that observed in clinical studies of Atazanavir in pediatric patients taking Atazanavir capsules. The most common Grade 3–4 laboratory abnormalities occurring in pediatric patients weighing 10 kg to less than 25 kg taking Atazanavir oral powder were increased amylase (19%), neutropenia (12%), increased SGPT/ALT (5%), elevation of total bilirubin ( ≥ 2.6 times ULN, 12%), increased lipase (5%), and decreased hemoglobin (3%). All other Grade 3–4 laboratory abnormalities occurred with a frequency of less than 3%.

Patients Co-Infected With Hepatitis B And/Or Hepatitis C Virus

In study AI424-138, 60 patients treated with Atazanavir/ritonavir 300 mg/100 mg once daily, and 51 patients treated with lopinavir/ritonavir 400 mg/100 mg twice daily, each with fixed dose tenofovir-emtricitabine, were seropositive for hepatitis B and/or C at study entry. ALT levels > 5 times ULN developed in 10% (6/60) of the Atazanavir/ritonavir-treated patients and 8% (4/50) of the lopinavir/ritonavir-treated patients. AST levels > 5 times ULN developed in 10% (6/60) of the Atazanavir/ritonavir-treated patients and none (0/50) of the lopinavir/ritonavir-treated patients.

In study AI424-045, 20 patients treated with Atazanavir/ritonavir 300 mg/100 mg once daily, and 18 patients treated with lopinavir/ritonavir 400 mg/100 mg twice daily, were seropositive for hepatitis B and/or C at study entry. ALT levels > 5 times ULN developed in 25% (5/20) of the Atazanavir/ritonavir-treated patients and 6% (1/18) of the lopinavir/ritonavir-treated patients. AST levels > 5 times ULN developed in 10% (2/20) of the Atazanavir/ritonavir-treated patients and 6% (1/18) of the lopinavir/ritonavir-treated patients.

In studies AI424-008 and AI424-034, 74 patients treated with 400 mg of Atazanavir once daily, 58 who received efavirenz, and 12 who received nelfinavir were seropositive for hepatitis B and/or C at study entry. ALT levels > 5 times ULN developed in 15% of the Atazanavir-treated patients, 14% of the efavirenz-treated patients, and 17% of the nelfinavir-treated patients. AST levels > 5 times ULN developed in 9% of the Atazanavir-treated patients, 5% of the efavirenztreated patients, and 17% of the nelfinavir-treated patients. Within Atazanavir and control regimens, no difference in frequency of bilirubin elevations was noted between seropositive and seronegative patients.

Postmarketing Experience

The following events have been identified during postmarketing use of Atazanavir. Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Body as a Whole: edema

Cardiovascular System: second-degree AV block, third-degree AV block, left bundle branch block, QTc prolongation

Gastrointestinal System: pancreatitis

Hepatic System: hepatic function abnormalities

Hepatobiliary Disorders: cholelithiasis, cholecystitis, cholestasis

Metabolic System and Nutrition Disorders: diabetes mellitus, hyperglycemia

Musculoskeletal System: arthralgia

Renal System: nephrolithiasis, interstitial nephritis

Skin and Appendages:alopecia, maculopapular rash, pruritus, angioedema

Atazanavir contraindications

See also:
What is the most important information I should know about Atazanavir?

Atazanavir is contraindicated:

in patients with previously demonstrated clinically significant hypersensitivity (eg, Stevens-Johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of Atazanavir capsules or Atazanavir oral powder.
when coadministered with drugs that are highly dependent on CYP3A or UGT1A1 for clearance, and for which elevated plasma concentrations of the interacting drugs are associated with serious and/or life-threatening events.
when coadministered with drugs that strongly induce CYP3A and may lead to lower exposure and loss of efficacy of Atazanavir.

Table 6 displays drugs that are contraindicated with Atazanavir.

Table 6: Drugs that are Contraindicated with Atazanavir (Information in the table applies to Atazanavir with or without ritonavir, unless otherwise indicated)
a See Drug Interactions, Table 16 (7) for parenterally administered midazolam.

b See Drug Interactions, Table 16 (7) for sildenafil when dosed as VIAGRA® for erectile dysfunction.

Drug Class

Drugs within class that are contraindicated with Atazanavir

Clinical Comment

Alpha 1-Adrenoreceptor Antagonist

Alfuzosin

Potential for increased alfuzosin concentrations, which can result in hypotension.

Antimycobacterials

Rifampin

Rifampin substantially decreases plasma concentrations of Atazanavir, which may result in loss of therapeutic effect and development of resistance.

Antineoplastics

Irinotecan

Atazanavir inhibits UGT1A1 and may interfere with the metabolism of irinotecan, resulting in increased irinotecan toxicities.

Benzodiazepines

Triazolam, orally administered midazolama

Triazolam and orally administered midazolam are extensively metabolized by CYP3A4. Coadministration of triazolam or orally administered midazolam with Atazanavir may cause large increases in the concentration of these benzodiazepines. Potential for serious and/or life-threatening events such as prolonged or increased sedation or respiratory depression.

Ergot Derivatives

Dihydroergotamine, ergotamine, ergonovine, methylergonovine

Potential for serious and/or life-threatening events such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.

GI Motility Agent

Cisapride

Potential for serious and/or life-threatening reactions such as cardiac arrhythmias.

Herbal Products

St. John’s wort (Hypericum perforatum)

Coadministration of St. John’s wort and Atazanavir may result in loss of therapeutic effect and development of resistance.

HMG-CoA Reductase Inhibitors

Lovastatin, simvastatin

Potential for serious reactions such as myopathy, including rhabdomyolysis.

Neuroleptic

Pimozide

Potential for serious and/or life-threatening reactions such as cardiac arrhythmias.

PDE5 Inhibitor

Sildenafilb when dosed as REVATIO® for the treatment of pulmonary arterial hypertension

Potential for sildenafil-associated adverse events (which include visual disturbances, hypotension, priapism, and syncope).

Protease Inhibitors

Indinavir

Both Atazanavir and indinavir are associated with indirect (unconjugated) hyperbilirubinemia.

Non-nucleoside Reverse Transcriptase Inhibitors

Nevirapine

Nevirapine substantially decreases Atazanavir exposure which may result in loss of therapeutic effect and development of resistance. Potential risk for nevirapine-associated adverse reactions due to increased nevirapine exposures.



Active ingredient matches for Atazanavir:

Atazanavir


Unit description / dosage (Manufacturer)Price, USD
Capsule; Oral; Atazanavir Sulfate 100 mg
Capsule; Oral; Atazanavir Sulfate 150 mg
Capsule; Oral; Atazanavir Sulfate 200 mg
Reyataz 300 mg capsule$ 36.63
Reyataz 150 mg capsule$ 18.49
Reyataz 200 mg capsule$ 18.49
Reyataz 100 mg capsule$ 18.12

List of Atazanavir substitutes (brand and generic names):

ATAVIR 300MG CAPSULE 1 strip / 30 capsules each (Cipla Ltd)$ 36.51
Capsule; Oral; Atazanavir Sulfate 100 mg (Bristol-Myers Squibb)
Capsule; Oral; Atazanavir Sulfate 150 mg (Bristol-Myers Squibb)
Capsule; Oral; Atazanavir Sulfate 200 mg (Bristol-Myers Squibb)
Capsule; Oral; Atazanavir Sulfate 300 mg (Bristol-Myers Squibb)
Reyataz 150 mg x 60's (Bristol-Myers Squibb)
Reyataz 200 mg x 60's (Bristol-Myers Squibb)
Reyataz 300 mg x 30's (Bristol-Myers Squibb)
30 capsule in 1 bottle, plastic (Bristol-Myers Squibb)
60 capsule in 1 bottle, plastic (Bristol-Myers Squibb)
Reyataz 100 mg x 60's (Bristol-Myers Squibb)
Reyataz 300 mg x 60's (Bristol-Myers Squibb)
Reyataz cap 200 mg 60's (Bristol-Myers Squibb)
Reyataz cap 300 mg 30's (Bristol-Myers Squibb)
Reyataz cap 300 mg 60's (Bristol-Myers Squibb)
Reyataz capsule, gelatin coated 200 mg/1 (Bristol-Myers Squibb)
Reyataz capsule 300 mg (Bristol-Myers Squibb)
Reyataz Capsule, hard 300 mg (Bristol-Myers Squibb)
Reyataz capsule, gelatin coated 150 mg/1 (Bristol-Myers Squibb)
Reyataz Capsule, hard 150 mg (Bristol-Myers Squibb)
Reyataz capsule, gelatin coated 300 mg/1 (Bristol-Myers Squibb)
Reyataz Oral powder 50 mg (Bristol-Myers Squibb)
Reyataz powder 50 mg/1 (Bristol-Myers Squibb)
Reyataz capsule 100 mg (Bristol-Myers Squibb)
Reyataz capsule 150 mg (Bristol-Myers Squibb)
Reyataz Capsule, hard 100 mg (Bristol-Myers Squibb)
Reyataz Capsule, hard 200 mg (Bristol-Myers Squibb)
Reyataz capsule 200 mg (Bristol-Myers Squibb)
300 mg x 30's (Genx (Hetero Healthcare Ltd))$ 33.33
Virataz 300 mg Capsule (Genx (Hetero Healthcare Ltd))$ 1.11
Virataz 300mg CAP / 30 (Genx (Hetero Healthcare Ltd))$ 33.33
VIRATAZ 300MG CAPSULE 1 strip / 30 capsules each (Genx (Hetero Healthcare Ltd))$ 33.33
VIRATAZ cap 300 mg x 30's (Genx (Hetero Healthcare Ltd))$ 33.33
Virataz 300mg CAP / 30 (Genx (Hetero Healthcare Ltd))$ 33.33
Virataz 300mg Capsule (Genx (Hetero Healthcare Ltd))$ 1.11

References

  1. PubChem. "Atazanavir". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
  2. DrugBank. "Atazanavir". http://www.drugbank.ca/drugs/DB01072 (accessed September 17, 2018).
  3. MeSH. "HIV Protease Inhibitors". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Atazanavir are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Atazanavir. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported useful

No survey data has been collected yet


Consumer reported price estimates

No survey data has been collected yet


Consumer reported time for results

No survey data has been collected yet


Consumer reported age

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 16 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2019 ndrugs.com All Rights Reserved